Glaxosmithkline Share News (GSK)

Tuesday broker round-up

Antofagasta: Jefferies reiterates buy. GlaxoSmithKline: Credit Suisse reiterates underperform and 1440p target. Micro Focus Intl.: Numis reiterates add and ups target price to 1,310p from 1,240p. Rockhopper Exploration: Canaccord Genuity starts coverage at buy and raises target to 190p from 180p.

Dividends Calendar - Week Ahead

Dividends Calendar - Week Ahead

BUZZ-U.S. STOCKS ON THE MOVE-GoDaddy, Twitter, Pier 1, Michael Kors

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks dipped at the open on Wednesday as a weaker-than-expec

BUZZ-U.S. STOCKS ON THE MOVE-Macerich, Coherus, EveryWare Global

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks dipped at the open on Wednesday as a weaker-than-expec

BUZZ-U.S. STOCKS ON THE MOVE-Coherus, Chesapeake, airline stocks

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock index futures pointed to a lower open on Wednesday as a

BUZZ-GlaxoSmithKline Plc: Shingles vaccine could be better than Merck's - Cowen

** Drugmaker's U.S.-listed shares up 1.3 pct at $46.75 premarket, London-listed up nearly 2 pct ** Cowen & Co analysts say GSK's vaccine to treat shingles may be more effective than Merck's ** Glaxo's vaccine HZ/su should be well positioned to capture market share from Merck's Zostava

WINNERS & LOSERS: Evraz Up On USD375 Million Return To Shareholders

BROKER RATINGS SUMMARY: Jefferies Upgrades Lloyds To Hold

BUZZ-U.S. STOCKS ON THE MOVE-Rada Electronic, Intercept Pharma, Alon USA

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell on Tuesday in a modest retreat from the previous

BUZZ-U.S. STOCKS ON THE MOVE-Lorillard, Charter Communications, Synta Pharma

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell at the open on Tuesday, slightly reversing the pr

BUZZ-U.S. STOCKS ON THE MOVE-Conn's, Lorillard, GW Pharma, DryShips

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock were poised to open lower on Tuesday, indicating a mode

BUZZ-U.S. STOCKS ON THE MOVE-Synta Pharma, Lorillard, BioCryst, Insmed

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock index futures were lower on Tuesday, indicating a modes

BUZZ-U.S. STOCKS ON THE MOVE-Synta Pharma, Teck Resources, GSK, Groupon

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock index e-mini futures fell on Tuesday: Dow Jones industr

UPDATE 1-J&J, Glaxo settle U.S. lawsuit over allergy ads

(Updates with Glaxo comment in 3rd paragraph) By Nate Raymond NEW YORK, March 30 (Reuters) - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share. The settlem